Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Shares Outstanding for 16 consecutive years, with $23.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 9.5% to $23.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.1 million through Dec 2025, up 9.5% year-over-year, with the annual reading at $23.1 million for FY2025, 9.5% up from the prior year.
  • Shares Outstanding hit $23.1 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $23.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $23.1 million in Q4 2025 to a low of $12.8 million in Q3 2021.
  • Historically, Shares Outstanding has averaged $19.1 million across 5 years, with a median of $20.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 45721.43% in 2021 and later crashed 99.95% in 2025.
  • Year by year, Shares Outstanding stood at $16.9 million in 2021, then grew by 4.32% to $17.6 million in 2022, then rose by 17.5% to $20.7 million in 2023, then increased by 1.82% to $21.1 million in 2024, then grew by 9.5% to $23.1 million in 2025.
  • Business Quant data shows Shares Outstanding for ANIP at $23.1 million in Q4 2025, $11000.0 in Q3 2025, and $22.3 million in Q2 2025.